Many team members at Unicorn Nest are Ukrainians affected by Russian aggression. We do our best to solve any issues and answer your questions in the shortest possible time frames but some delays are possible.

3E Bioventures

Overview

Investments

Unlock datapoints

Portfolio analytics

Team

News & Media

Add fund to favorites
info
Save this fund for later to form your own custom list of funds
This summary is composed by our algorithm based on the analysis of the deals. If you think that some of this information is not accurate, please let us know about it and provide any supporting evidences if possible. Such cases will be analyzed by our ML-algorithm and implemented in our database, which will improve this summary.

Need help with fundraising?

We offer an assisted fundraising option for startups

Learn more
Total investments 49
Average round size
info
The average size of a deal this fund participated in
$30M
Portfolio companies 35
Rounds per year 5.44
Lead investments 11
Follow on index
info
How often the fund supports its portfolio startups at next rounds
0.27
Exits 1
Key employees 2

Areas of investment

  • Biotechnology
  • Health Care
  • Medical
  • Biopharma
  • Medical Device
Summary

The venture was found in Asia in China. The main department of described VC is located in the Beijing.

Among the most successful fund investment fields, there are Genetics, Clinical Trials. Among the most popular portfolio startups of the fund, we may highlight Ansun BioPharma, Profusa, Apexigen. For fund there is no match between the country of its foundation and the country of its the most frequent investments - United States. The fund has no exact preference in a number of founders of portfolio startups. In case when startup counts 5+ of the founder, the chance for it to get the investment is meager. Moreover, a startup needs to be at the age of 6-10 years to get the investment from the fund.

The standard case for the fund is to invest in rounds with 3-4 partakers. Despite the 3E Bioventures, startups are often financed by SDIC Venture Capital, BioVeda China Fund, Morningside Group. The meaningful sponsors for the fund in investment in the same round are CMB International Capital Corporation, WuXi Healthcare Ventures, Shangbay Capital. In the next rounds fund is usually obtained by WuXi Healthcare Ventures, VT Ventures, Tasly Pharmaceutical.

Speaking about the real fund results, this VC is 9 percentage points more often commits exit comparing to other organizations. The high activity for fund was in 2018. The fund is constantly included in 2-6 deals per year. The common things for fund are deals in the range of 10 - 50 millions dollars.

Read more

Related Funds

Funds investing in previous rounds
These funds often invest in the rounds preceeding the rounds of 3E Bioventures:
Typical Co-investors
3E Bioventures is more likely to invest in rounds together with the following funds:
Funds investing in following rounds
These funds have a tendency to invest in the following rounds after 3E Bioventures:
There are no funds here. If we find new data, we will add it here.

Notable deals

CompanyIndustryRound SizeDateInvestorsLocation

Myrobalan Therapeutics

Biotechnology
Health Care
Therapeutics
$24M10 Jan 2024 Medford, Massachusetts, United States

Jushu Biotech

Biopharma
Biotechnology
Genetics
Medical
$15M17 Nov 2023 Changping, Beijing, China

Smartlens

Health Care
Health Diagnostics
Home Health Care
Medical
Medical Device
Personal Health
$6M11 Jul 2023 San Jose, California, United States

Novlead Biotech

Biotechnology
Medical
Pharmaceutical
24 Jun 2023 Nanjing, Jiangsu, China

Eaglenos

Health Care
Manufacturing
Medical
$23M29 May 2023 Nanjing, Jiangsu, China

Larkspur Biosciences

Biotechnology
Health Care
Medical
$35M23 May 2023 Watertown, Massachusetts, United States

Xunyuan Technology

Biopharma
Health Care
Medical
28 Apr 2023 Chongqing, Chongqing Shi, China

Eluminex Biosciences

Health Diagnostics
Therapeutics
$40M27 Feb 2023 Suzhou, Jiangsu, China

Junhemeng Biopharmaceutical

Biopharma
Biotechnology
Medical
$13M16 Jan 2023 Hangzhou, Zhejiang, China
News
Cullgen Closes $50 Million Series B Investment to Advance Targeted Protein Degraders and Novel E3 Ligands Platform

– Cullgen Inc. closed a $50m Series B financing (assuming exercise of warrant).
– The round was led by 3E Bioventures Capital, as well as Heights Capital Management (an affiliate of Susquehanna International Group), Octagon Capital, MSA Capital and South China Venture Capital.
– The financing will support the development of Cullgen’s technology platform and internal pipeline of targeted protein degraders in oncology and other diseases.
– Frank Yan, from 3E Bioventures, will be joining Cullgen’s board of directors.
– Cullgen is also pleased to announce that Frank Yan, from 3E Bioventures, will be joining Cullgen’s board of directors.

Review

  • No reviews are submitted yet.
Do you want more?
We provide dozens of additional datapoints about this fund.
Sign up and get access to full fund profile and advanced analysis.
Full team
Industries heatmap
Stages heatmap
Georgaphy breakdown
Coinvestors
Portfolio analysis
Performance indexes
Latest highlights
Unlock all data
Do you represent 3E Bioventures?
Get access to manage this page
Get in touch
Found incorrect info? Let us know!
Total investments 49
Average round size 30M
Rounds per year 5.44
Peak activity year 2021
Lead investments 11
Follow on index 0.27
Exits 1
Group Appearance index 0.88

Latest deals

CompanyIndustryRound SizeDateInvestorsLocation

Myrobalan Therapeutics

Biotechnology
Health Care
Therapeutics
$24M10 Jan 2024 Medford, Massachusetts, United States

Jushu Biotech

Biopharma
Biotechnology
Genetics
Medical
$15M17 Nov 2023 Changping, Beijing, China

Smartlens

Health Care
Health Diagnostics
Home Health Care
Medical
Medical Device
Personal Health
$6M11 Jul 2023 San Jose, California, United States

Novlead Biotech

Biotechnology
Medical
Pharmaceutical
24 Jun 2023 Nanjing, Jiangsu, China

Eaglenos

Health Care
Manufacturing
Medical
$23M29 May 2023 Nanjing, Jiangsu, China

Larkspur Biosciences

Biotechnology
Health Care
Medical
$35M23 May 2023 Watertown, Massachusetts, United States

Xunyuan Technology

Biopharma
Health Care
Medical
28 Apr 2023 Chongqing, Chongqing Shi, China

Eluminex Biosciences

Health Diagnostics
Therapeutics
$40M27 Feb 2023 Suzhou, Jiangsu, China

Junhemeng Biopharmaceutical

Biopharma
Biotechnology
Medical
$13M16 Jan 2023 Hangzhou, Zhejiang, China
Crunchbase icon

Content report

The following text will be sent to our editors: